AbbVie Inc. $ABBV Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 2.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 603,918 shares of the company’s stock after selling 13,133 shares during the period. AbbVie comprises approximately 0.5% of State of New Jersey Common Pension Fund D’s holdings, making the stock its 25th biggest holding. State of New Jersey Common Pension Fund D’s holdings in AbbVie were worth $137,989,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its position in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after purchasing an additional 3,032,438 shares during the last quarter. Raymond James Financial Inc. grew its stake in AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. Alliancebernstein L.P. increased its position in AbbVie by 31.8% in the third quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company’s stock worth $1,685,918,000 after buying an additional 1,758,657 shares during the period. Finally, Amundi boosted its holdings in shares of AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after acquiring an additional 1,414,621 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Trading Up 5.6%

AbbVie stock opened at $208.84 on Thursday. AbbVie Inc. has a 1-year low of $176.57 and a 1-year high of $244.81. The firm’s fifty day simple moving average is $214.80 and its 200-day simple moving average is $221.67. The company has a market capitalization of $369.27 billion, a P/E ratio of 87.93, a P/E/G ratio of 0.71 and a beta of 0.38.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, missing the consensus estimate of $3.01 by ($0.36). AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter last year, the business earned $2.46 earnings per share. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. On average, equities research analysts predict that AbbVie Inc. will post 14.21 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Analyst Upgrades and Downgrades

Several research firms recently commented on ABBV. The Goldman Sachs Group restated a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Royal Bank Of Canada started coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target for the company. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Finally, UBS Group cut their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $252.38.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 results: Revenue of $15.00B beat consensus and AbbVie raised 2026 adjusted EPS guidance to $14.08–$14.28, citing Skyrizi/Rinvoq strength. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Bank of America upgraded ABBV from Neutral to Buy and set a $234 price target, supporting upside vs. current levels.
• Positive Sentiment: Regulatory progress: AbbVie submitted FDA applications/label-expansion filings for Rinvoq (upadacitinib) in alopecia areata and other indications — potential sales tailwind if approved. AbbVie Submits Application to FDA for Upadacitinib
• Positive Sentiment: Pipeline/BD: AbbVie holds an option/warrant around Kestrel (KRAS program) that could lead to up to $1.45B in deal value and expands oncology exposure. AbbVie sinks talons into KRAS with right to buy Kestrel
• Positive Sentiment: Partner milestone: EvolveImmune nomination triggered an $18M milestone payment tied to its AbbVie collaboration — near‑term non‑core cash positive. EvolveImmune Therapeutics Announces Achievement
• Neutral Sentiment: Allergan Aesthetics (AbbVie unit) launched a May philanthropic campaign via Allē — positive PR but limited direct financial impact. Allergan Aesthetics Launches Philanthropic Effort
• Neutral Sentiment: Valuation commentary: Several analyst pieces are re‑assessing AbbVie after recent price weakness; useful for longer‑term investors but not an immediate catalyst. Assessing AbbVie Valuation
• Negative Sentiment: Analyst revisions: Erste Group trimmed FY2026/FY2027 EPS estimates modestly (small downward revisions) — a warning that some sell‑side forecasts are being re‑tuned.
• Negative Sentiment: Legacy declines: Humira and Imbruvica continue to contract; though newer immunology and neuroscience products offset much of the decline, legacy erosion remains a structural headwind. AbbVie tops quarterly expectations

Insider Transactions at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.